Partnering with BI Sincerely, Yours - Boehringer Ingelheim

Dr. Christine Grygon
Venture Capital Liaison/BI Partnership
Ridgefield, CT
Phone: +1 203 798 5651
Fax: +1 203 837 5651
E-mail: christine.grygon@boehringer-ingelheim.com
We believe in the value of building strong relationships with traditional and non-traditional
healthcare-related organizations investing in the next wave of therapeutic treatments.
Close contacts to key players in the biotechnology and pharmaceutical world such as venture
capitalists and other investors are of major importance to us. With a dedicated liaison, we
are committed to building close connections to the VC community, investment banking
community, entrepreneurs, incubators and not-for-profit organizations as potential partners
in order to advance innovation toward commercialization and the benefit of patients. We
also seek to connect with non-traditional partners such as healthcare providers, managed
care organizations, information technology, contract research and generics companies in
order to understand the ground-breaking technologies these organizations will invest in
to prepare for the future of healthcare.
Through continuing dialog with investors, biotech companies, and contacts in the pharmaceutical
business, we monitor trends in innovation with potential to benefit patients in unexpected ways.
External Outreach
Key Areas for Dialog and Partnering
• Emerging technologies that bring
treatments beyond molecules with the
potential to impact our pipeline and
prescription medicines business
• Technologies beyond research, including:
• Delivery technologies for biologics,
including formulations, devices, and
molecular targeting approaches
• Patient compliance and health
monitoring technologies
• E-health solutions
• Robust relationships with VC community
and their portfolio companies.
• Engaging to contribute a ‘pharma’
perspective on diverse topics such as
business development paradigms or
preferred animal models in the industry
12 External Outreach
13